PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Mosunetuzumab→

Mosunetuzumab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1905409-39-3
Molecular formula
Not available
Molecular weight
Not available
Drug class
CD20-directed CD3 T-cell-engaging bispecific monoclonal antibodyantineoplastic biologic
Mechanism of action
Binds CD20 on B cells and CD3 on T cells, bringing T cells into proximity with malignant B cells and inducing T-cell activation and B-cell lysis.
Indications / reported uses
  • Treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy under the US product indication; EU product indications and line-of-therapy requirements should be checked separately

Sources: US DailyMed — LUNSUMIO (mosunetuzumab-axgb) · EMA EPAR — Lunsumio · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Mosunetuzumab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Mosunetuzumab Permitted Daily Exposure (PDE) report (the Mosunetuzumab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Mosunetuzumab Occupational Exposure Limit (OEL) report (the Mosunetuzumab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.